Valuation: Agenus Inc.

Market Cap 145M 127M 117M 109M 206M 13.84B 210M 1.4B 545M 6.8B 546M 534M 23.44B P/E 2026 *
4.45x
P/E 2027 * -19.4x
Enterprise Value 145M 127M 117M 109M 206M 13.84B 210M 1.4B 545M 6.8B 546M 534M 23.44B EV / Sales 2026 *
0.79x
EV / Sales 2027 * 1.11x
Free-Float
93.28%
Yield 2026 *
-
Yield 2027 * -
1 day+2.35%
1 week+15.18%
Current month+14.05%
1 month+8.39%
3 months+4.80%
6 months+8.05%
Current year+11.15%
1 week 2.96
Extreme 2.96
3.52
1 month 2.85
Extreme 2.85
3.52
Current year 2.71
Extreme 2.71
5.08
1 year 2.71
Extreme 2.71
7.34
3 years 1.38
Extreme 1.38
38.6
5 years 1.38
Extreme 1.38
135.8
10 years 1.38
Extreme 1.38
149.8
Manager TitleAgeSince
Chief Executive Officer 72 31/03/1994
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 01/11/2021
Director TitleAgeSince
Chairman 72 04/11/2010
Director/Board Member 68 08/03/2007
Director/Board Member 68 07/12/2006
Date Insider Type Main position Quantity % Market Cap.
06-26Free

Chief Executive Officer

5,364 0.0129%
06-12Free

Chief Executive Officer

4,925 0.0118%
05-29Free

Chief Executive Officer

4,644 0.0112%
Change 5-day change 1-year change 3-year change Capi.($)
+2.35%+15.18%-42.50%-88.52% 145M
+1.70%+7.41%+3.12%+8.46% 49.92B
+0.92%+3.93%+399.71%+605.33% 40.23B
+1.89%+8.32%+26.06%-6.35% 34.55B
+2.38%+6.35%+21.25%+64.58% 33.09B
+3.96%+10.67%+11.89%+38.86% 27.51B
+2.51%+5.27% - - 17.05B
+2.58%+5.79%+73.44%+133.27% 15.92B
+0.32%+0.58%+13.67%+19.09% 13.86B
+3.30%+0.76%+90.23%+99.12% 13.52B
Average +2.19%+7.36%+66.32%+97.10% 24.58B
Weighted average by Cap. +2.07%+6.54%+90.66%+137.60%

Financials

2026 *2027 *
Net sales 185M 161M 148M 138M 262M 17.59B 266M 1.78B 693M 8.64B 693M 678M 29.79B 131M 115M 106M 98.44M 187M 12.52B 190M 1.27B 493M 6.15B 493M 483M 21.2B
Net income 46M 40.21M 36.96M 34.45M 65.34M 4.38B 66.33M 444M 172M 2.15B 173M 169M 7.42B -9.9M -8.65M -7.95M -7.41M -14.06M -943M -14.27M -95.48M -37.12M -463M -37.16M -36.36M -1.6B
Net Debt - -
Logo Agenus Inc.
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.
Employees
81
Date Price Change Volume
02/07/26 $3.490 +2.35% 680,579
01/07/26 $3.410 +11.44% 660,413
30/06/26 $3.060 -2.86% 644,548
29/06/26 $3.150 +3.96% 947,439
26/06/26 $3.030 +5.21% 5,006,329
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.490USD
Average target price
15.50USD
Spread / Average Target
+344.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGEN Stock